We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+39.03%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$520M
Cap. Flow
+$202M
Cap. Flow %
12.68%
Top 10 Hldgs %
83.78%
Holding
29
New
7
Increased
2
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$181M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$52.8M
3
CCCC icon
C4 Therapeutics
CCCC
+$47.6M
4
SLDB icon
Solid Biosciences
SLDB
+$13.4M
5
APTX
Aptinyx Inc. Common Stock
APTX
+$11.6M

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$48.9M
2
SAGE
Sage Therapeutics
SAGE
+$30.5M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22M
4
KYMR icon
Kymera Therapeutics
KYMR
+$12.2M
5
PANA.U
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 93.91%
2 Financials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.47B
$2.84M 0.18%
+250,000
New +$2.65M
REPL icon
27
Replimune Group
REPL
$1.28B
– –
-2,122,415
Closed -$48.9M
SAGE
28
DELISTED
Sage Therapeutics
SAGE
– –
-499,100
Closed -$30.5M
PANA.U
29
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
– –
-500,000
Closed -$5M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q4 2020 Portfolio in Review

As of Q4 2020, Bain Capital Life Sciences Investors held 29 positions worth $1.59B, up 48% from $1.07B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Bain Capital Life Sciences Investors deployed $202M of net new capital in Q4 2020, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was Atea Pharmaceuticals: 5,615,659 shares worth $235M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $22M trimmed.

  • Bain Capital Life Sciences Investors's largest Q4 2020 buy was Atea Pharmaceuticals: 5,615,659 shares worth $235M.
  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q4 2020, an estimated $13.4M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2020 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $22M.
  • Bain Capital Life Sciences Investors fully exited Replimune Group in Q4 2020, selling an estimated $48.9M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 84% of its $1.59B portfolio in Q4 2020.
  • Bain Capital Life Sciences Investors opened 7 new positions and closed 3 in Q4 2020.
  • Bain Capital Life Sciences Investors's portfolio value rose 48% quarter-over-quarter to $1.59B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2020, filed 16 Feb 2021.